Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2025
Event: Announcement of an in-person and virtual R&D Day scheduled for October 14, 2025, at 8:00 a.m. ET.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely as a notification of an upcoming corporate event and the availability of a presentation.
Material Changes
No material changes to financial position or operations are reported in this filing. The primary disclosure is the scheduling of the R&D Day and the furnishing of the accompanying presentation as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The company will host an R&D Day with a webcast available via the Investors section of its website. A presentation accompanies this filing.
Legal Status of Information: In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and is not subject to the liability of that section. It is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the date and time of the R&D Day (October 14, 2025, 8:00 a.m. ET).
- Access the webcast and presentation materials via the company's Investor Relations website.
- Note that the presentation content is furnished, not filed, and carries different legal liability standards than standard SEC filings.
- Review the presentation (Exhibit 99.1) for any forward-looking statements or clinical updates, as this 8-K does not contain those details directly.